SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 5th, 2021 • Tyme Technologies, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of February 4, 2021, between Tyme Technologies, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
Tyme Technologies, Inc. 8,000,000 Shares of Common Stock and Warrants to Purchase up to 8,000,000 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • April 2nd, 2019 • Tyme Technologies, Inc. • Pharmaceutical preparations • New York
Tyme Technologies, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom Canaccord Genuity LLC is acting as representative (the “Representative”), (i) 8,000,000 shares (the “Shares”) of common stock, par value $ 0.0001 per share, of the Company (the “Common Stock”) and (ii) warrants to purchase 8,000,000 shares of Common Stock (the “Warrants,” and together with the Shares, the “Securities”). The respective number of Securities to be purchased by each Underwriter is set forth opposite its name in Schedule 1 hereto. The shares of Common Stock underlying the Warrants are referred to herein as the “Warrant Shares.” The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • October 18th, 2019 • Tyme Technologies, Inc. • Pharmaceutical preparations • New York
WARRANT TO PURCHASE PREFERRED STOCK OF TYME TECHNOLOGIES, INC.Warrant Agreement • August 8th, 2017 • Tyme Technologies, Inc. • Pharmaceutical preparations • New York
WARRANT TO PURCHASE PREFERRED STOCK (this “Agreement”), dated as of between TYME TECHNOLOGIES, INC., a Delaware corporation (the “Company”), and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).
TYME TECHNOLOGIES, INC. and , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF [ ], 20Debt Securities Warrant Agreement • August 8th, 2017 • Tyme Technologies, Inc. • Pharmaceutical preparations • New York
DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of between TYME TECHNOLOGIES, INC., a Delaware corporation (the “Company”), and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).
STRICTLY CONFIDENTIAL Tyme Technologies, Inc.Exclusive Agency Agreement • February 5th, 2021 • Tyme Technologies, Inc. • Pharmaceutical preparations • New York
FORM OF REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 11th, 2015 • Tyme Technologies, Inc. • Wholesale-beer, wine & distilled alcoholic beverages • New York
TYME TECHNOLOGIES, INC. AND [●], Trustees INDENTURE Dated as of [__________], 20[__]Indenture • July 21st, 2016 • Tyme Technologies, Inc. • Pharmaceutical preparations • New York
THIS INDENTURE, dated as of [_____], 2016, between TYME TECHNOLOGIES, INC., a Delaware corporation (the “Issuer”), and [•], a national banking association organized and existing under the laws of the United States (the “Trustee”),
TYME TECHNOLOGIES, INC. EQUITY DISTRIBUTION AGREEMENTEquity Distribution Agreement • November 6th, 2017 • Tyme Technologies, Inc. • Pharmaceutical preparations • New York
Tyme Technologies, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Canaccord Genuity Inc. (“Canaccord”), as follows:
SPLIT-OFF AGREEMENTSplit-Off Agreement • March 11th, 2015 • Tyme Technologies, Inc. • Wholesale-beer, wine & distilled alcoholic beverages • Florida
This SPLIT-OFF AGREEMENT, dated as of March 5, 2015 (this “Agreement”), is entered into by and among Tyme Technologies, Inc. (f/k/a Global Group Enterprises Corp.), a Delaware corporation (the “Seller”), Global Group Enterprises Global Group Enterprises Inc., a Florida corporation(“Split-Off Subsidiary”), and Andrew Keck (“Buyer”).
TYME TECHNOLOGIES, INC.Employment Agreement • May 22nd, 2020 • Tyme Technologies, Inc. • Pharmaceutical preparations • New York
This letter sets forth our agreement with respect to your employment (hereinafter “letter agreement”) with Tyme Technologies, Inc., a Delaware corporation (the “Company”).
SYROS PHARMACEUTICALS, INC. [FORM OF] SUPPORT AGREEMENTSupport Agreement • July 5th, 2022 • Tyme Technologies, Inc. • Pharmaceutical preparations • Delaware
This Support Agreement (this “Agreement”) is made and entered into as of [•], 2022, by and among Tyme Technologies, Inc. a Delaware corporation (“Tyme”), Syros Pharmaceuticals, Inc., a Delaware corporation (“Syros”), and the undersigned stockholder (the “Stockholder”) of Syros.
CO-PROMOTION AGREEMENT by and between TYME TECHNOLOGIES, INC. And EAGLE PHARMACEUTICALS, INC. January 7, 2020Co-Promotion Agreement • May 22nd, 2020 • Tyme Technologies, Inc. • Pharmaceutical preparations • Delaware
This Co-Promotion Agreement (this “Agreement”) is entered into and dated as of January 7, 2020 (the “Effective Date”) by and between Tyme Technologies, Inc., a Delaware corporation (“TYME”), and Eagle Pharmaceuticals, Inc., a Delaware corporation (“Eagle”). TYME and Eagle are each referred to individually as a “Party” and together as the “Parties”.
TYME TECHNOLOGIES, INC. New York, New York 10005Employment Agreement • February 2nd, 2016 • Tyme Technologies, Inc. • Pharmaceutical preparations • New York
This letter (this “letter agreement”) sets forth our agreement with respect to your employment with Tyme Technologies, Inc., a Delaware corporation (the “Company”).
EXCHANGE AGREEMENTExchange Agreement • May 20th, 2020 • Tyme Technologies, Inc. • Pharmaceutical preparations • New York
This Exchange Agreement (the “Agreement”) is entered into as of the day of May, 2020, by and between Tyme Technologies, Inc., a Delaware corporation (the “Company”), and the undersigned holder of the Existing Warrant (as defined below) (the “Holder”), with reference to the following facts:
TYME TECHNOLOGIES, INC. 1 PLUCKEMIN WAY - SUITE 103 BEDMINSTER NJ 07921Employment Agreement • May 25th, 2022 • Tyme Technologies, Inc. • Pharmaceutical preparations • New Jersey
This letter sets forth our agreement with respect to your employment (hereinafter “letter agreement”) with Tyme Technologies, Inc., a Delaware corporation (the “Company”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 8th, 2016 • Tyme Technologies, Inc. • Pharmaceutical preparations • Delaware
This Securities Purchase Agreement, dated as of February 2, 2016, is by and between Tyme Technologies, Inc., a Delaware corporation with its principal offices at 48 Wall Street, Suite 1100, New York, NY 10005 (the “Company”), and the persons listed as the Purchasers on Schedule A to this Agreement (each, a “Purchaser”).
TYME TECHNOLOGIES, INC. New York, New York 10005Employment Agreement • March 11th, 2015 • Tyme Technologies, Inc. • Wholesale-beer, wine & distilled alcoholic beverages • New York
This letter (this “letter agreement”) sets forth our agreement with respect to your employment with Tyme Technologies, Inc., a Delaware corporation (the “Company”).
LOCK-UP AGREEMENTLock-Up Agreement • March 11th, 2015 • Tyme Technologies, Inc. • Wholesale-beer, wine & distilled alcoholic beverages • New York
This LOCK-UP AGREEMENT (this “Agreement”) is made as of March 5, 2015 (the “Effective Date”), by and between the undersigned person or entity (the “Restricted Holder”) and Tyme Technologies, Inc., a Delaware corporation formerly known as Global Group Enterprises Corp. (the “Company”). Capitalized terms used and not otherwise defined herein shall have the meanings given to such terms in the Merger Agreement (as defined herein).
Holder] [Address] [Address] [Address]Leak-Out Agreement • May 20th, 2020 • Tyme Technologies, Inc. • Pharmaceutical preparations • New York
This agreement (the “Leak-Out Agreement”) is being delivered to you in connection with that certain understanding by and between Tyme Technologies, Inc., a Delaware corporation (the “Company”) and the undersigned (“Holder”).
Tyme Technologies, Inc. Amended & Restated Nonqualified Stock Option AgreementNonqualified Stock Option Agreement • July 31st, 2018 • Tyme Technologies, Inc. • Pharmaceutical preparations
This Amended and Restated Nonqualified Stock Option Agreement (the “Agreement”), dated July 30, 2018, (the “Effective Date”) is made by and between Tyme Technologies, Inc., a Delaware corporation (the “Company”), and Ben R. Taylor (the “Optionee”).
Tyme Technologies, Inc. Option AgreementOption Agreement • February 2nd, 2016 • Tyme Technologies, Inc. • Pharmaceutical preparations
Tyme Technologies, Inc., a Delaware corporation (the “Company”), pursuant to the Company’s 2015 Equity Incentive Plan (the “Plan”), has granted to Robert Dickey IV (the “Optionee”) a stock option (the “Option”) to purchase a total of 200,000 shares (each, a “Share”) of the common stock, par value $0.0001 per share (the “Common Stock”), of the Company, at the exercise price of $11.00 per Share (the “Exercise Price”), on the terms and conditions set forth in this Option Agreement (this “Agreement”) and, in all respects, subject to the terms and conditions of the Plan. The effective date of grant of the Option is January 27, 2016 (the “Date of Grant”). Unless otherwise defined herein, the capitalized terms defined in the Plan shall have the same defined meanings in this Agreement.
TYME TECHNOLOGIES, INC. New York, New York 10005 August 1, 2017Employment Agreement • November 3rd, 2017 • Tyme Technologies, Inc. • Pharmaceutical preparations • New York
This letter (this “letter agreement”) sets forth our agreement with respect to your employment with Tyme Technologies, Inc., a Delaware corporation (the “Company,” “we” or “us” as applicable).
VOTING AGREEMENTVoting Agreement • May 25th, 2022 • Tyme Technologies, Inc. • Pharmaceutical preparations • Delaware
VOTING AGREEMENT, dated as of March 24, 2022 (this “Agreement”), by and between Tyme Technologies, Inc., a Delaware corporation (the “Company”), and Steve Hoffman (the “Stockholder”).
TYME TECHNOLOGIES, INC. 2016 STOCK OPTION PLAN FOR NON-EMPLOYEE DIRECTORS NONQUALIFIED STOCK OPTION AWARD AGREEMENTNonqualified Stock Option Award Agreement • June 12th, 2019 • Tyme Technologies, Inc. • Pharmaceutical preparations • Delaware
THIS AGREEMENT is made on ___________ (the “Date of Grant”), by and between Tyme Technologies, Inc., a Delaware corporation (the “Company”), and __________ (the “Participant”).
TYME TECHNOLOGIES, INC. 2016 STOCK OPTION PLAN FOR NON-EMPLOYEE DIRECTORS CONTINGENT NONQUALIFIED STOCK OPTION AWARD AGREEMENTStock Option Agreement • May 29th, 2018 • Tyme Technologies, Inc. • Pharmaceutical preparations • Delaware
THIS AGREEMENT is made on (the “Date of Grant”), by and between Tyme Technologies, Inc., a Delaware corporation (the “Company”), and (the “Participant”).
Second Amendment to Release AgreementRelease Agreement • September 6th, 2022 • Tyme Technologies, Inc. • Pharmaceutical preparations
This Amendment (the “Second Amendment”), effective as of September 2, 2022, is entered into by and between Tyme Technologies, Inc., a Delaware corporation (the “Company”), and Michael Demurjian (the “Stockholder”).
TYME TECHNOLOGIES, INC.Employment Agreement • February 3rd, 2021 • Tyme Technologies, Inc. • Pharmaceutical preparations • New Jersey
This amended and restated letter (this “letter agreement”) sets forth our agreement with respect to your employment with Tyme Technologies, Inc., a Delaware corporation (the “Company”).
RELEASE AGREEMENTRelease Agreement • June 12th, 2019 • Tyme Technologies, Inc. • Pharmaceutical preparations • New York
This Release Agreement (this “Release Agreement”) is made by and between Tyme Technologies, Inc. and Michael Demurjian on this 15th day of March, 2019.
Tyme Technologies, Inc. Nonqualified Stock Option AgreementNonqualified Stock Option Agreement • April 2nd, 2018 • Tyme Technologies, Inc. • Pharmaceutical preparations • Delaware
Tyme Technologies, Inc., a Delaware corporation (the “Company”), pursuant to the Tyme Technologies, Inc. 2015 Equity Incentive Plan (the “Plan”), has granted to (the “Optionee”) a nonqualified stock option (the “Option”) to purchase a total of shares (each, a “Share”) of the common stock (the “Common Stock”) of the Company, at an exercise price equal to $ (the “Exercise Price”), on the terms and conditions set forth in this Option Agreement (this “Agreement”) and, in all respects, subject to the terms and conditions of the Plan. The effective date of grant of the Option is (the “Date of Grant”). Unless otherwise defined herein, the capitalized terms defined in the Plan shall have the same defined meanings in this Agreement.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • January 8th, 2020 • Tyme Technologies, Inc. • Pharmaceutical preparations • Delaware
This REGISTRATION RIGHTS AGREEMENT (the “Agreement”) is made as of January 7, 2020 by and between Tyme Technologies, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), and Eagle Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Purchaser”).
TYME TECHNOLOGIES, INC. 2016 STOCK OPTION PLAN FOR NON-EMPLOYEE DIRECTORS CONTINGENT NONQUALIFIED STOCK OPTION AWARD AGREEMENTContingent Nonqualified Stock Option Award Agreement • May 29th, 2018 • Tyme Technologies, Inc. • Pharmaceutical preparations • Delaware
THIS AGREEMENT is made on (the “Date of Grant”), by and between Tyme Technologies, Inc., a Delaware corporation (the “Company”), and (the “Participant”).
WARRANT TO PURCHASE COMMON STOCK OF TYME TECHNOLOGIES, INC.Warrant Agreement • March 22nd, 2017 • Tyme Technologies, Inc. • Pharmaceutical preparations
This certifies that, for value received, ___________ (“Holder”) is entitled, subject to the terms and conditions set forth below, to purchase from Tyme Technologies, Inc. (the “Company”), in whole or in part ___________ fully paid and nonassessable shares (the “Warrant Shares”) of common stock, par value $0.0001 per share (“Common Stock”), of the Company, at a purchase price of $3.00 per Warrant Share (the “Exercise Price”). The number, character and Exercise Price of such shares of Common Stock are subject to adjustment only as provided in Section 8 and 9 below and all references to “Warrant Shares” and “Exercise Price” herein shall be deemed to include any such adjustment or series of adjustments. The term “Warrant” as used herein shall mean this Warrant, and any warrants delivered in substitution or exchange therefor as provided herein.
LICENSE AGREEMENTLicense Agreement • March 11th, 2015 • Tyme Technologies, Inc. • Wholesale-beer, wine & distilled alcoholic beverages • Delaware
THIS LICENSE AGREEMENT (the “Agreement”), executed as of July 9, 2014 (“Effective Date”), is made by and between Steven Hoffman, an individual residing at 15 Knichel Road, Mahwah, New Jersey 07430 (hereinafter “Hoffman”), and Tyme, Inc., a corporation organized under the laws of the State of Delaware, having a place of business at 2711 Centerville Road, Suite 400, Wilmington, Delaware 19808 (hereinafter “Tyme”). Hoffman and Tyme are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Company Letterhead]Cooperation Agreement • September 6th, 2022 • Tyme Technologies, Inc. • Pharmaceutical preparations • New Jersey
Under the terms of your April 28, 2022 retention letter agreement (your “April 2022 Retention Agreement”), you are eligible to receive a retention bonus when Tyme Technologies, Inc. (the “Company”) completes its merger (the “Merger”) with Syros Pharmaceuticals, Inc. (“Syros”). The Company is pleased to offer you additional benefits in exchange for providing assistance to the Company from today through the 90-day period following the date that it completes the Merger (the “Cooperation Period”), subject to the terms and conditions set forth in this letter agreement (the “Cooperation Agreement”).
